Irinotecan Hydrochloride [100286-90-6]
Cat# T0486L-1ml
Size : 1mLx10mM(inDMSO)
Brand : TargetMol
Contact local distributor :
Phone : +1 850 650 7790
Irinotecan Hydrochloride
(Synonyms: CPT-11 hydrochloride, Camptothecin 11 hydrochloride) Copy Product Info
Irinotecan Hydrochloride (CPT-11 hydrochloride) is the hydrochloride salt of a semisynthetic derivative of camptothecin. Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.
Cas No. 100286-90-6
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.94%
Color:White to Yellow
COA HPLC HNMR
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Irinotecan Hydrochloride (CPT-11 hydrochloride) is the hydrochloride salt of a semisynthetic derivative of camptothecin. Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent. |
| In vitro | Increasing concentrations of Irinotecan (0.1, 1, 10, 100, and 1000 μg/mL) inhibits the growth of all cell lines in a dose-dependent manner. COLO-357 cells are most sensitive and HT29 most resistant to Irinotecan in the MTT assay on incubation for 90 min. The IC50 concentrations are 100, 50, 5.4, 23 and 46 μg/mL Irinotecan for HT29, NMG 64/84, COLO-357, MIA PaCa-2 and PANC-1, respectively[1]. |
| In vivo | The time course of body weight change after Irinotecan (100 mg/kg i.p.) injection shows a significant dosing time-dependent difference (P<0.01). Mean maximum body weight loss is observed between days 3 and 4 after Irinotecan (CPT-11) injection. The minimum mean body weight loss is observed after Irinotecan (CPT-11) injection at 1700 hr. Moreover, the maximum mean body weight loss is observed after Irinotecan injection at 0500 or 0900 hr[2]. |
| Synonyms | CPT-11 hydrochloride, Camptothecin 11 hydrochloride |
| Cell Research | Irinotecan hydrochloride is dissolved in DMSO and stored, and then diluted with appropriate medium before use[1]. To determine the effects of Irinotecan in combination with 5-FU, the MTT assay is used. Depending on the cell lines, 10,000 to 20,000 cells per well are seeded in 96-well plates and incubated for 24 h in complete medium. On day 2, cells are incubated in the absence or presence of Irinotecan for 30 min followed by 5-FU for 24 h. After another 24 h in complete medium without any additives, MTT reagent is added on day 4 to initiate the assay and the cells are incubated for an additional 4 h at 37°C. After removal of the medium and dissolving the crystals with acidified isopropanol, the samples are analyzed using an ELISA plate reader at 570 nm. The value at 650 nm is subtracted as background[1]. |
| Molecular Weight | 623.14 |
| Formula | C33H39ClN4O6 |
| Cas No. | 100286-90-6 |
| Smiles | Cl.CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 65 mg/mL (104.31 mM), Sonication is recommended.  H2O: 3.12 mg/mL (5.01 mM), Heating is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (8.02 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||||||||||||||||||||||